Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Current Assets (2016 - 2025)

Avanos Medical (AVNS) has disclosed Current Assets for 13 consecutive years, with $355.4 million as the latest value for Q4 2025.

  • Quarterly Current Assets fell 9.66% to $355.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $355.4 million through Dec 2025, down 9.66% year-over-year, with the annual reading at $355.4 million for FY2025, 9.66% down from the prior year.
  • Current Assets hit $355.4 million in Q4 2025 for Avanos Medical, up from $351.4 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $624.1 million in Q4 2022 to a low of $351.4 million in Q3 2025.
  • Historically, Current Assets has averaged $444.5 million across 5 years, with a median of $445.7 million in 2021.
  • Biggest five-year swings in Current Assets: dropped 28.65% in 2021 and later soared 45.95% in 2022.
  • Year by year, Current Assets stood at $427.6 million in 2021, then skyrocketed by 45.95% to $624.1 million in 2022, then fell by 21.97% to $487.0 million in 2023, then fell by 19.22% to $393.4 million in 2024, then fell by 9.66% to $355.4 million in 2025.
  • Business Quant data shows Current Assets for AVNS at $355.4 million in Q4 2025, $351.4 million in Q3 2025, and $356.0 million in Q2 2025.